Regulating Drug Pricing

Chamath and Jason discuss the need for regulation in drug pricing, questioning the transparency of the FDA's decision-making process and the economic implications of allowing unlimited pricing for drugs. They also highlight the problematic incentives in Medicare Part B that contribute to rising healthcare expenses.